CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(02): 101-108
DOI: 10.1055/s-0041-1729479
Original Article

A Study on the Serum γ-Glutamyltranspeptidase and Plasma Osteopontin in Alcoholic Liver Disease

Arpita Suri
1   Department of Biochemistry, Faculty of Medicine and Health Sciences, SGT University, Gurugram, Haryana, India
Naveen Singh
1   Department of Biochemistry, Faculty of Medicine and Health Sciences, SGT University, Gurugram, Haryana, India
Sanjiv Kumar Bansal
1   Department of Biochemistry, Faculty of Medicine and Health Sciences, SGT University, Gurugram, Haryana, India
› Author Affiliations


Background Alcoholic liver disease (ALD) is a major source of alcohol-related morbidity and mortality. Heavy drinkers and alcoholics may progress from fatty liver to alcoholic hepatitis to cirrhosis. The enzyme γ-glutamyltranspeptidase (GGT) is a membrane-bound glycoprotein which catalyzes the transfer of the γ-glutamyl group from γ-glutamyl peptides to other peptides, amino acids, and water. Serum GGT activity mainly attributed to hepatobiliary system and thus is an important marker of ALD. Hence the present study is conducted to estimate and correlate the levels of GGT and osteopontin (OPN) in ALD.

Aims and Objectives The objective of this study is to estimate and correlate the levels of GGT and OPN in ALD.

Materials and Methods Sixty clinically diagnosed cases of ALD and sixty age- and gender-matched healthy controls were recruited for the study. Blood samples were collected from them and serum aspartate aminotransferase, serum alanine transaminases (ALTs), serum ALP levels, and plasma OPN levels were measured. Estimation of serum aspartate transaminases (AST), ALTs, and alkaline phosphatase (ALP) was assayed by standard photometric methods in autoanalyzer ERBA-XL (EM-200) using commercially available kits. OPN was estimated by using commercial kit based on enzyme-linked immunosorbent assay.

Results The parameters of the liver function tests such as AST, ALT, and ALP were significantly increased in patients with ALD (p < 0.001) when compared with the healthy control subjects. In the present study, significantly increased levels of γ-glutamyl transferases and OPN were found in patients with ALD (p < 0.001) when compared with the control subjects. OPN showed significant positive correlations with AST (r = 0.76, p < 0.001), ALT (r = 0.64, p < 0.001), ALP (r = 0.68, p < 0.001), and GGT (r = 0.61, p < 0.001).

Conclusion The present study focuses on the role of GGT and OPN that are sensitive indicators of liver cell injury and are most helpful in recognizing hepatocellular diseases such as ALD, hepatitis, and liver cirrhosis. Hence, the pattern of the GGT and OPN levels elevation can be helpful diagnostically.

Publication History

Article published online:
09 July 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Savolainen VT, Liesto K, Männikkö A, Penttilä A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res 1993; 17 (05) 1112-1117
  • 2 Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999; 48 (04) 184-188
  • 3 Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health 2003; 27 (03) 209-219
  • 4 MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6 (03) 221-232
  • 5 Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9 (01) 37-53
  • 6 Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004; 24 (03) 217-232
  • 7 Bellentani S, Saccoccio G, Costa G. et al. The Dionysos Study Group. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997; 41 (06) 845-850
  • 8 Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008; 154 (02) 299-315
  • 9 Thapa BR, Walia A. Liver function tests and their interpretation. Indian J Pediatr 2007; 74 (07) 663-671
  • 10 Cuschieri A, Baker PR. Gamma-glutamyl-transpeptidase in hepato-biliary disease—value as an enzymatic liver function test. Br J Exp Pathol 1974; 55 (02) 110-115
  • 11 Mauro P, Renze B, Wouter W. In: Carl AB, Edward R, David EB, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Philadelphia, PA: Elsevier 2006: 604-616
  • 12 Nagoshi S. Osteopontin: versatile modulator of liver diseases. Hepatol Res 2014; 44 (01) 22-30
  • 13 Wen Y, Jeong S, Xia Q, Kong X. Role of osteopontin in liver diseases. Int J Biol Sci 2016; 12 (09) 1121-1128
  • 14 Oldberg A, Franzén A, Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986; 83 (23) 8819-8823
  • 15 Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995; 270 (44) 26232-26238
  • 16 Denda S, Reichardt LF, Müller U. Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell 1998; 9 (06) 1425-1435
  • 17 Diana Nicoll C. Appendix: therapeutic drug monitoring and laboratory reference ranges. In: Stephen JM, Maxine AP, eds. Current medical diagnosis and treatment. 46th ed. New York, NY: McGraw Hill 2007: 1767-1775
  • 18 Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16 (04) 885-893
  • 19 Konttinen A, Härtel G, Louhija A. Multiple serum enzyme analyses in chronic alcoholics. Acta Med Scand 1970; 188 (04) 257-264
  • 20 Matloff DS, Selinger MJ, Kaplan MM. Hepatic transaminase activity in alcoholic liver disease. Gastroe-nterology 1980; 78 (06) 1389-1392
  • 21 Moussavian SN, Becker RC, Piepmeyer JL, Mezey E, Bozian RC. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Dig Dis Sci 1985; 30 (03) 211-214
  • 22 Das SK, Vasudevan DM. Biochemical diagnosis of alcoholism. Indian J Clin Biochem 2005; 20 (01) 35-42
  • 23 Maithreyi R, Janani AV, Krishna R, Shweta A, Edwin RR, Mohan SK. Erythrocyte lipid peroxidation and antioxidants in chronic alcoholics with alcoholic liver disease. Asian J Pharm Clin Res 2010; 3: 183-185
  • 24 Mirunalini S, Arulmozhi V, Arulmozhi T. Curative effect of garlic on alcoholic liver diseased patients. Jordan J Biol Sci 2010; 3 (04) 147-152
  • 25 Jang ES, Jeong SH, Hwang SH. et al. Effects of coffee, smoking, and alcohol on liver function tests: a comprehensive cross-sectional study. BMC Gastroenterol 2012; 12 (01) 145
  • 26 Al-Jumaily EF. The effect of chronic liver diseases on some biochemical parameters in patients serum. Curr Res J Biol Sci 2012; 4 (05) 638-642
  • 27 Hyder MA, Hasan M, Mohieldein AH. Comparative levels of ALT, AST, ALP and GGT in liver associated diseases. Eur J Exp Biol 2013; 3 (02) 280-284
  • 28 Gayathri B, Vasantha M. Comparative levels of liver enzymes in patients with various liver disorders. Int J Pharma Bio Sci 2015; 6 (04) 1099-1102
  • 29 Brandl K, Hartmann P, Jih LJ. et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol 2018; 69 (02) 396-405
  • 30 Hourigan KJ, Bowling FG. Alcoholic liver disease: a clinical series in an Australian private practice. J Gastroenterol Hepatol 2001; 16 (10) 1138-1143
  • 31 Seth D, Duly A, Kuo PC, McCaughan GW, Haber PS. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation. World J Gastroenterol 2014; 20 (36) 13088-13104
  • 32 Teschke R, Neuefeind M, Nishimura M, Strohmeyer G. Hepatic gamma-glutamyltransferase activity in alcoholic fatty liver: comparison with other liver enzymes in man and rats. Gut 1983; 24 (07) 625-630
  • 33 Benerji GV, Babu FM, Kumari RD, Saha A. Comparative study of ALT, AST, GGT & uric acid levels in liver diseases. IOSR-JDMS 2013; 7 (05) 72-75
  • 34 Agarwal S, Fulgoni VL, Lieberman HR. Assessing alcohol intake & its dose dependent effects on liver enzymes by 24-h recall and questionnaire using NHANES 2001-2010 data. Nutrition Journal 2016; 15-62
  • 35 Arai M, Yokosuka O, Kanda T. et al. Serum osteopontin levels in patients with acute liver dysfunction. Scand J Gastroenterol 2006; 41 (01) 102-110
  • 36 Zhao L, Li T, Wang Y. et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008; 62 (07) 1056-1062
  • 37 Patouraux S, Bonnafous S, Voican CS. et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012; 7 (04) e35612
  • 38 Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma osteopontin level in chronic liver disease and hepatocellular carcinoma. Hepat Mon 2015; 15 (09) e30753
  • 39 Gogoi JB, Tyagi PK, Singh AK, Gairola K. Study of serum gamma glutamyltransferase as a diagnostic marker in alcoholic hepatitis. J Pharm 2012; 2 (04) 69-71
  • 40 Srungaram P, Rule JA, Yuan HJ. et al. Acute Liver Failure Study Group. Plasma osteopontin in acute liver failure. Cytokine 2015; 73 (02) 270-276